GUFICBIO Gufic Biosciences Q2 FY25 results (Jul–Sep 2024) and concall
Gufic Biosciences reported a slight decline in Q2 FY25 revenue and PAT year-over-year, primarily attributed to capacity constraints at Navsari and API pricing erosion, with the new Indore facility commencing production only in early October. Despite the short-term challenges, the company is strategically positioning Indore for future growth, focusing on domestic contract manufacturing and eventual entry into regulated markets like the EU and US. Management highlighted progress in various divisions, including critical care, ferticare, aestaderm, neurocare, and international business, while ackn
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 204 |
| EBITDA | 39 |
| Net profit | 22 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
